Area of research
Molecular Biology · Cancer Research
Research interest
Research focused on Cancer research and Cisplatin, with related work in Gene knockdown, Adenocarcinoma, SMAD. Notable publications include 'TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA', 'A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma', and 'm 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma'.
m <sup>6</sup> A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma
m<sup>6</sup>A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma
DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma
Targeting piRNA‐137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via <i>De Novo</i> Cholesterol Biosynthesis in Lung Adenocarcinoma
TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA
A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma
LINC02678 as a Novel Prognostic Marker Promotes Aggressive Non-small-cell Lung Cancer
Identification of Differentially Expressed and Prognostic lncRNAs for the Construction of ceRNA Networks in Lung Adenocarcinoma
Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy
CUEDC1 inhibits epithelial-mesenchymal transition via the T&#x3B2;RI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer
PHLPP2 as a novel metastatic and prognostic biomarker in non‐small cell lung cancer patients